Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#How Has The Anti-Cancer MAbS Market Size Shifted, And What Is the Outlook Through 2034?

Over recent years, the anti-cancer mabs market has witnessed notable expansion. It is anticipated to scale up from a value of $69.33 billion in 2024 to $76.92 billion in 2025 with a compound annual growth rate (CAGR) of 11.0%. The substantial growth in the past can be credited to factors such as the growth in cancer incidence rates, better knowledge about cancer biology, uptick in personalized medicine strategies, increased funding in research and development, along with heightened patient awareness and demand.

How Much Will the Anti-Cancer MAbS Market Be Worth in 2029?

Predictions indicate robust expansion in the anti-cancer mabs market in the upcoming years, with expectations to reach $109.88 billion by 2029, reflecting a compound annual growth rate (CAGR) of 9.3%. Several factors fuel this predicted growth, including advances in immunotherapy, increased use of combination therapies, the advent of next-generation mAbs, universal attempts to mitigate cancer, and the growth of patient access programs. The forecast period also anticipates trends such as the development of drug delivery technologies, the application of artificial intelligence in drug discovery, alliances and partnerships within the pharmaceutical industry, advancements in biotechnology, and car-t cell therapies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9041&type=smp

Which is the Largest Company in the Anti-Cancer MAbS Market?

Major companies operating in the anti-cancer mabs market include Amgen Inc., Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Novartis AG, Merck & Co. Inc., Spectrum Pharmaceuticals Inc., AstraZeneca plc., Pfizer Inc., Gilead Sciences Inc., Bayer HealthCare, ImmunoGen Inc., Genentech Inc., AbbVie Inc., Takeda Pharmaceuticals, Seattle Genetics, Regeneron Pharmaceuticals, Celgene, Ipsen, Daiichi Sankyo, Kite Pharma, ADC Therapeutics, MacroGenics Inc., BioXcel Therapeutics, Zymeworks Inc., Exelixis Inc., Blueprint Medicines, Erytech Pharma, Oncopeptides AB

What Are the Main Market Drivers in the Anti-Cancer MAbS Industry?

The growth of the anticancer MABs market is expected to be driven by the growing global incidence of cancer. Often a chronic, long-lasting condition, cancer has led to an increase in demand for Anticancer monoclonal antibodies (mAbs). These mAbs are specifically engineered to attach to proteins found on cancer cells, leveraging modified versions of the immune system’s own antibodies to target and eliminate cancer cells. Thus, the rising occurrence of cancer directly impacts the demand for the anticancer MABs market. For example, PubMed, an American biomedical and life science journal, predicted in January 2022 that around 1.9 million new cases of cancer would be diagnosed worldwide, with 609,360 of these cases resulting in deaths in the United States. Consequently, the escalating global prevalence of cancer is driving the growth of the anticancer mAbs market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=9041&type=smp

How Is the Anti-Cancer MAbS Market Segments Structured?

The anti-cancer mabs market covered in this report is segmented –

1) By Type: Murine Antibodies, Chimeric Antibodies, Humanized Antibodies, Other Types

2) By Application: Blood Cancer, Breast Cancer, Lung Cancer, Melanoma, Colorectal Cancer, Liver Cancer, Other Applications

3) By End User: Hospitals, Research Institutes, Other End Users

Subsegments:

1) By Murine Antibodies: Murine IgG, Murine IgM, Other Murine Isotypes

2) By Chimeric Antibodies: Chimeric IgG, Chimeric IgM, Other Chimeric Isotypes

3) By Humanized Antibodies: Humanized IgG, Humanized IgM, Other Humanized Isotypes

4) By Other Types: Fully Human Antibodies, Bispecific Antibodies, Conjugated Antibodies, Other Novel Formats

What Strategic Trends Are Transforming the Anti-Cancer MAbS Market?

In the anticancer mAbs industry, the development of new products is becoming a significant trend. Top-tier companies in the market are introducing more advanced and effective cancer treatments, specifically mAbs drugs, to solidify their market status. Recently in May 2022, Roche Holding AG, a pharmaceutical company based in Switzerland, announced the launch of PHESGO. PHESGO, which combines pertuzumab, trastuzumab, and hyaluronidase-zzxf, is a novel monoclonal antibody (mAb) combination therapy for patients with HER2-positive early breast cancer. This unique subcutaneous (administered under the skin) injection couples the two mAbs, pertuzumab and trastuzumab, with the enzyme hyaluronidase. The inclusion of hyaluronidase helps to enhance the absorption of the mAbs, which allows this therapy to be delivered subcutaneously, an alternative to the intravenous method.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/anti-cancer-mabs-global-market-report

Which Global Regions Offer the Highest Growth in the Anti-Cancer MAbS Market?

The countries covered in the anti-cancer mAbs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9041

This Report Delivers Insight On:

1. How big is the anti-cancer mabs market, and how is it changing globally?

2. Who are the major companies in the anti-cancer mabs market, and how are they performing?

3. What are the key opportunities and risks in the anti-cancer mabs market right now?

4. Which products or customer segments are growing the most in the anti-cancer mabs market?

5. What factors are helping or slowing down the growth of the anti-cancer mabs market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model